
-
Dynavax Technologies NasdaqGS:DVAX Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Location: 2100 Powell Street, Suite 900, EmeryVille, CA, 94608, United States | Website: https://www.dynavax.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
800.8M
Cash
661.3M
Avg Qtr Burn
N/A
Short % of Float
15.08%
Insider Ownership
0.55%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MVC-COV1901 Details COVID-19 Vaccine | Approved Update | |
Heplisav-B Details Infectious disease, Hepatitis B vaccine, Hepatitis B | Approved Quarterly sales | |
CpG 1018 Details COVID-19 | Approved Quarterly sales | |
COVID-19 S-Trimer (with Clover Biopharmaceuticals) Details Infectious disease, COVID-19 | Approved Quarterly sales | |
Heplisav-B Details Infectious disease, Hepatitis B vaccine, Hepatitis B | BLA Resubmission | |
Phase 2 Initiation | ||
Z-1018 (adjuvanted w/ CpG 1018) Details Shingles, Infectious disease, Viral infection | Phase 1/2 Data readout | |
VLA2001 Details Infectious disease, COVID-19 | Failed Discontinued | |
Tdap-1018 (adjuvanted w/ CpG 1018) Details Infectious disease, Tetanus, diphtheria, and pertussis | Failed Discontinued |